Aignosis, a Jaipur-based healthcare technology company, secured ₹4 crore in seed funding led by Antler, with backing from Zerodha co-founder Nikhil Kamath, Acko founder Varun Dua, and IIMA Ventures, the company announced October 1. The capital arrives as the startup's webcam-based autism screening platform reaches 21 government primary health centers across Rajasthan, where it screened 1,622 children in its first year.
The timing reflects mounting pressure on pediatric screening infrastructure worldwide. When the American Academy of Pediatrics surveyed primary care physicians in 2026, the results painted a stark picture: 96% reported shortages in developmental-behavioral pediatrics, and child psychiatry gaps hit 97%. India's psychiatric workforce hovers around 0.8 per 100,000 people, according to a 2025 Commonwealth Fund profile, leaving neurodevelopmental assessment out of reach for most families in tier-two cities and rural districts.
England's National Health Service counted 294,792 patients waiting for autism referrals as of June 2026, NHS Digital reported for the twelve months through mid-year. Early intervention hinges on early detection, but wait times measured in years erase the narrow windows when therapy makes the greatest difference.
Workforce Gaps Meet Regulatory Openings
Computer vision tools are moving into that void, pushed by forces that have little to do with technology elegance and everything to do with system capacity. The CDC's most recent surveillance report, published in April 2025 using 2022 data, put U.S. autism prevalence at roughly 1 in 31 eight-year-olds. Universal screening at 18 and 24 months, which the AAP reaffirmed in 2024, generates referral volumes that subspecialists simply cannot absorb.
India's regulatory environment opened a path that might have taken years elsewhere. The Central Drugs Standard Control Organisation issued final guidance on medical device software in July, clarifying risk classifications under the 2017 Medical Device Rules. Class B devices covering low-to-moderate-risk applications can secure state-level licensing rather than navigating federal approval cycles that stretch across multiple years. Aignosis used that framework to deploy in government facilities after obtaining Class B certification.
Market researchers have taken notice. Stratistics Market Research Consulting projected the AI-based neurodevelopment screening sector will expand from $2.8 billion this year to $12.6 billion by 2034, a compound annual growth rate above 20%. Future Market Insights put separate numbers on autism diagnostics broadly, forecasting growth from $4.3 billion to $13.3 billion over the next decade, driven partly by AI adoption.
Whether those projections prove accurate depends less on algorithm performance than on reimbursement infrastructure and clinical acceptance, variables that remain unsettled.
Distribution Over Technology
Aignosis runs nine stimulus modules on standard laptop webcams during sessions lasting three to five minutes. Computer vision algorithms track gaze patterns, response-to-name, and facial reactions, then output a risk report that health workers use when deciding referrals. "This funding marks a shift for Aignosis from building and validating the technology to taking it into the healthcare system at scale," co-founder Raksheet Jain said in a statement.
The distribution strategy separates the company from clinic-only competitors, though perhaps more than the founders initially anticipated. Aignosis partnered with Mankind Pharma, leveraging approximately 1,300 medical representatives to support screening camps with pediatricians nationwide. Apollo Hospitals' Shines school program began rolling out the tool across roughly 125 schools. "Most healthcare innovation in India is built for the top of the pyramid," Kamath said. "Aignosis is going the other way... That's distribution thinking."
The U.S. regulatory landscape offers two instructive precedents. Cognoa's Canvas Dx received FDA De Novo authorization in June 2021 and a subsequent 510(k) clearance in April 2025 for children aged 18 to 72 months. The device combines caregiver questionnaires, clinician assessments, and video analysis reviewed by trained analysts working alongside machine learning systems. Wyoming Medicaid became the first state program to cover Canvas Dx in September 2024. Cognoa reported commercial reimbursement from Highmark in October.
EarliPoint Health holds FDA 510(k) clearances dated 2022, 2025, and as recently as March for an eye-tracking biomarker device validated in JAMA and JAMA Network Open last September. The device measures social visual engagement in children aged 16 to 95 months. "We are bringing the first and only FDA-cleared eye-tracking biomarker to the world of autism," CEO Jamie Pagliaro wrote on LinkedIn. Marcus Autism Center launched the EarliPoint Evaluation in clinic in August 2023.
Academic labs are accelerating model development outside proprietary frameworks. Nature Communications published a pretrained vision-language model for naturalistic caregiver-child interaction screening in September. npj Digital Medicine detailed a fully automated home-video pipeline in October 2025 using open-source components: COCO-based pose estimation, YOLOv8 object detection, OpenAI's Whisper for speech-to-text. The work demonstrated feasibility of low-cost deployments without proprietary licenses, though clinical validation at scale remains outstanding.
Reimbursement and Real-World Performance
Payer willingness to cover objective screening tools will determine adoption speed more than any technical breakthrough. Cognoa CEO Sharief Taraman called on insurers in April 2025 to "make early, accurate diagnosis accessible to all families" as CDC data showed rising prevalence. Real-world evidence from 254 Canvas Dx prescriptions showed a determinate rate around 60.5% with strong positive and negative predictive values, a peer-reviewed analysis found last year. The findings illustrate both the tool's utility and the reality that clinical judgment remains essential when outputs land in indeterminate ranges.
Demographic generalizability and explainability remain unresolved. Multiple reviews published this year emphasized the need for clinician-interpretable metrics and validation across race, ethnicity, and sex before widespread primary-care adoption becomes defensible. A Springer Nature review called for explainable, scalable eye-gaze models to bridge what researchers termed the bench-to-practice gap.
Regulatory navigation will shape international expansion for companies eyeing markets beyond their home jurisdictions. The EU AI Act's transparency obligations took effect in August, with high-risk requirements phasing in through December 2027. Medical-device AI typically qualifies as high-risk under the AI Act, though classification remains under the Medical Device Regulation, according to guidance issued in April by the Medical Device Coordination Group.
Founders building in this space and health systems evaluating tools face similar questions. Watch for reimbursement pathway standardization across jurisdictions, not product feature announcements. The technical validation exists. Payment infrastructure and care-pathway integration lag well behind. That gap, more than algorithm accuracy, will decide which screening tools reach scale and which remain confined to pilot programs and research collaborations.
